KC1036
2 abstracts
Abstract
First-in-human, phase I study of KC1036, a multiple kinase inhibitor, as a single agent in patients with advanced solid tumors.Org: Clinical Trial Center and Department of Epidemiology - IRCCS Ospedale Policlinico San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy, National Medical Products Administration Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, West China Hospital, State Key Laboratory of Biotherapy, Sichuan University,
Abstract
KC1036, a novel oral multi-kinase inhibitor, in patients with previously treated advanced esophageal squamous cell carcinoma (ESCC): Results from a multicenter, single-arm phase II trial.Org: National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Oncology Department, the First Affiliated Hospital of Xinxiang Medical College, Chongqing University Three Gorges Hospital & Chongqing Three Gorges Central Hospital, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Tianjin Medical University Cancer Institute & Hospital,National Clinical Research Center for Cancer,